ROR1 and neoplasm: However, it should be noted that on-target/off-tumor toxicity must be taken into consideration when using anti-ROR1 CAR-T because of its expression on other normal tissues, such as parathyroid, pancreatic islet cells, and gastrointestinal tract [52–55].